Utilization and budget impact of tolvaptan in the inpatient setting among patients with heart failure and hyponatremia. (4th March 2018)

• Record Type: Journal Article
• Authors: Amin, Alpesh N.; Ortendahl, Jesse D.; Harmon, Amanda L.; Kamat, Siddhesh A.; Stellhorn, Robert A.; Chase, Sandra L.; Sundar, Shirin V.
• Is Part Of: Current medical research and opinion. Volume 34:Number 3(2018)
• Page Start: 559
• Page End: 566
• Publication Date: 2018-03-04
• Subjects: Heart failure -- hyponatremia -- budget impact -- sodium -- hospitalization -- economic model -- tolvaptan; Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1080/03007995.2018.1423958
• Languages: English
• ISSNs: 0300-7995

Abstract

Abstract: Objective: Assess characteristics of patients with heart failure (HF) and hyponatremia (HN) using tolvaptan, a selective vasopressin V2-receptor antagonist, for sodium correction, and estimate the budget impact of tolvaptan use in a hospital. Methods: The Premier hospital database was analyzed to assess the utilization of tolvaptan, characteristics of users and non-users, and hospitalization costs among patients with HF and HN. Using these findings, a model was developed to estimate tolvaptan costs in proportion to total medical costs of managing patients with HF and HN, and the budget impact of tolvaptan use. Results were regenerated using data from the Healthcare Cost and Utilization Project (HCUP) database, and robustness was assessed in sensitivity analyses. Results: Tolvaptan was used in 4.96% of inpatient visits among patients with HF and HN, more commonly among sicker patients as reflected in high utilization during intensive care stays (30.46%). Additionally, utilization increased by length of stay, which can serve as a proxy for disease severity. The model estimated that tolvaptan costs accounted for 0.3% of total hospitalization-related costs for patients with HF and HN, and the budget impact was $52.42 per visit. Conclusions: Results demonstrate that tolvaptan is used infrequently among patients with HF and HN, and is utilized among sicker patients. Tolvaptan accounted for 0.3% of total spending on management of inpatient visits with HF and HN, and had a marginal impact on hospital budget when compared with fluid restriction for HN correction. Availability of tolvaptan can provide an additional therapeutic option for sodium correction.